Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
Want to see ELDN full AI Analyst Report?
Top Page
Eledon Pharmaceuticals
(NASDAQ:ELDN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.50
▼(-12.06% Downside)
Action:ReiteratedDate:04/24/26
The score is weighed down primarily by weak financial performance (no revenue, recurring losses, and ongoing cash burn that increased in 2025), despite low leverage on the balance sheet. Technicals are supportive of an uptrend but appear overbought, and valuation remains challenged due to unprofitability and no dividend support.
Positive Factors
Low leverage and balance-sheet flexibility
Very low debt gives Eledon structural financial flexibility: less cash required for interest, greater capacity to allocate capital to R&D or partnerships, and more optionality for non-dilutive financings or strategic transactions over the next 2–6 months as programs advance.
Negative Factors
No product revenue and sustained net losses
Absence of operating revenue means Eledon remains fully pre-commercial and reliant on external funding. Persistent net losses limit operating leverage and make long-term sustainability contingent on successful trials, approvals, or external financing rather than internal cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and balance-sheet flexibility
Very low debt gives Eledon structural financial flexibility: less cash required for interest, greater capacity to allocate capital to R&D or partnerships, and more optionality for non-dilutive financings or strategic transactions over the next 2–6 months as programs advance.
Read all positive factors
Eledon Pharmaceuticals (ELDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$286.72M
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS Growth61.62%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding75,851,720
10 Day Avg. Volume1,804,762
30 Day Avg. Volume1,596,014
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
$7.33Price Target Upside84.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Eledon Pharmaceuticals Business Overview & Revenue Model
Company Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its l...
How the Company Makes Money
Eledon Pharmaceuticals does not have a marketed product and therefore does not have recurring product sales revenue. Its historical and current funding is primarily generated through capital-raising activities such as issuing equity (e.g., common ...
Eledon Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -359.00K | -374.00K | -373.00K | -195.00K |
| EBITDA | -83.25M | -35.39M | -116.16M | -87.59M | -36.66M |
| Net Income | -45.62M | -36.18M | -116.54M | -87.97M | -34.51M |
Balance Sheet | |||||
| Total Assets | 237.60M | 177.41M | 89.07M | 92.79M | 170.55M |
| Cash, Cash Equivalents and Short-Term Investments | 133.34M | 140.18M | 51.10M | 56.41M | 84.83M |
| Total Debt | 641.00K | 954.00K | 383.00K | 746.00K | 769.00K |
| Total Liabilities | 100.82M | 59.27M | 81.86M | 8.61M | 6.55M |
| Stockholders Equity | 136.78M | 118.14M | 7.21M | 84.18M | 164.00M |
Cash Flow | |||||
| Free Cash Flow | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Operating Cash Flow | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Investing Cash Flow | 10.79M | -70.31M | -45.29M | 0.00 | 0.00 |
| Financing Cash Flow | 53.81M | 133.52M | 33.02M | 0.00 | -449.00K |
Eledon Pharmaceuticals Technical Analysis
Positive
3.98
Price Trends
2.72
Positive
2.25
Positive
2.60
Positive
Market Momentum
0.24
Negative
79.17
Negative
86.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELDN, the sentiment is Positive. The current price of 3.98 is above the 20-day moving average (MA) of 3.12, above the 50-day MA of 2.72, and above the 200-day MA of 2.60, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 79.17 is Negative, neither overbought nor oversold. The STOCH value of 86.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELDN.
Eledon Pharmaceuticals Risk Analysis
Eledon Pharmaceuticals disclosed 37 risk factors in its most recent earnings report. Eledon Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eledon Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $822.56M | -9.27 | -33.07% | ― | ― | -20.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $924.67M | -4.03 | -101.33% | ― | ― | -34.16% | |
48 Neutral | $286.72M | -2.73 | -46.46% | ― | ― | 61.62% | |
45 Neutral | $293.62M | -8.09 | -677.38% | ― | 25.40% | 34.67% | |
43 Neutral | $31.03M | -2.94 | 315.97% | ― | ― | -201.53% | |
41 Neutral | $33.21M | -1.38 | -81.31% | ― | -64.00% | 91.26% |
* Healthcare Sector Average
ELDN
Eledon Pharmaceuticals
3.80
0.80
26.67%
TVRD
Tvardi Therapeutics
3.66
-22.34
-85.92%
EDIT
Editas Medicine
3.18
1.84
138.72%
ANNX
Annexon Biosciences
5.70
4.01
237.28%
DSGN
Design Therapeutics
14.55
11.22
336.94%
TVGN
Tevogen Bio Holdings
7.07
-44.93
-86.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.